CLINICAL RESEARCH
Increased Activity of the Ubiquitin-Proteasome System in Patients With Symptomatic Carotid Disease Is Associated With Enhanced Inflammation and May Destabilize the Atherosclerotic Plaque
Effects of Rosiglitazone Treatment
Raffaele Marfella, MD, PhD*, ,*,
Michele D'Amico, PhD , ,
Clara Di Filippo, PhD , ,
Alfonso Baldi, MD ,
Mario Siniscalchi, MD, PhD*,
Ferndinando Carlo Sasso, MD, PhD*,
Michele Portoghese, MD||,
Ornella Carbonara, MD*,
Basilio Crescenzi, MD¶,
Paolo Sangiuolo, MD¶,
Giovanni Francesco Nicoletti, MD#,
Raffaele Rossiello, MD**,
Franca Ferraraccio, MD ,
Federico Cacciapuoti, MD*,
Mario Verza, MD*,
Ludovico Coppola, MD*,
Francesco Rossi, MD , and
Giuseppe Paolisso, MD, PhD*,
* Department of Geriatrics and Metabolic Diseases
"Centro di Eccellenza Cardiovascolare,"
Department of Experimental Medicine
Department of Biochemistry, Section of Pathology, Second University of Naples, Naples, Italy
|| Cardiovascular Surgery Unit, Sassari Hospital, Naples, Italy
¶ Cardiovascular Surgery Unit, Hospital V. Monaldi, Naples, Italy
# Department of Surgery, Second University of Naples, Naples, Italy
** Department of Biochemistry and Biophysics "F. Cedrangolo," Section of Anatomic Pathology, Second University of Naples, Naples, Italy
Manuscript received November 9, 2005;
revised manuscript received January 25, 2006,
accepted January 29, 2006.
* Reprint requests and correspondence: Dr. Raffaele Marfella, Via Emilio Scaglione 141, 80145 Napoli, Italy (Email: raffaele.marfella{at}unina2.it).
OBJECTIVES: We evaluated ubiquitin-proteasome activity in carotid plaques of asymptomatic and symptomatic patients and the effect of rosiglitazone, a peroxisome proliferator-activated receptor-gamma activator, in symptomatic plaques.
BACKGROUND: The role of the ubiquitin-proteasome system, the major pathway for non-lysosomal intracellular protein degradation in eucaryotic cells, in the progression of atherosclerotic plaque to instability is unclear.
METHODS: Plaques were obtained from 40 symptomatic and 38 asymptomatic patients undergoing carotid endarterectomy. Symptomatic patients received 8 mg rosiglitazone (n = 20) or placebo (n = 20) for 4 months before scheduled endarterectomy. Plaques were analyzed for macrophages (CD68), T-lymphocytes (CD3), inflammatory cells (HLA-DR), ubiquitin-proteasome activity, nuclear factor kappa B (NFkB), inhibitory kappa B (IkB)-beta, nitrotyrosine, matrix metalloproteinase (MMP)-9, and collagen content (immunohistochemistry and enzyme-linked immunosorbent assay).
RESULTS: Compared with asymptomatic plaques, symptomatic plaques had more macrophages, T-lymphocytes, and HLA-DR+ cells (p < 0.001); more ubiquitin-proteasome activity and NFkB (p < 0.001); and more markers of oxidative stress (nitrotyrosine and O2 production) and MMP-9 (p < 0.01) along with a lesser collagen content and IkB-beta levels (p < 0.001). Compared with placebo-treated plaques, rosiglitazone-treated symptomatic plaques presented fewer inflammatory cells (p < 0.01); less ubiquitin, proteasome 20S, and NFkB (p < 0.01); less nitrotyrosine and O2 production (p < 0.01); and greater collagen content (p < 0.01), indicating a more stable plaque phenotype.
CONCLUSIONS: Ubiquitin-proteasome overactivity is associated with enhanced inflammatory reaction in symptomatic plaques. The inhibition of ubiquitin-proteasome activity in lesions of symptomatic patients by rosiglitazone is associated with plaque stabilization, possibly by down-regulating NFkB-mediated inflammatory pathways.
|
Abbreviations and Acronyms
| | ELISA = enzyme-linked immunosorbent assay | | IkB = inhibitory kappa B | | MMP = matrix metalloproteinase | | NFkB = nuclear factor kappa B | | NO = nitric oxide | | PPAR = peroxisome proliferator-activated receptor | | TIA = transient ischemic attack | | VSMC = vascular smooth muscle cell |
|
This article has been cited by other articles:

|
 |

|
 |
 
Z. Yang, D. Gagarin, G. St. Laurent III, N. Hammell, I. Toma, C.-a. Hu, A. Iwasa, and T. A. McCaffrey
Cardiovascular Inflammation and Lesion Cell Apoptosis: A Novel Connection via the Interferon-Inducible Immunoproteasome
Arterioscler Thromb Vasc Biol,
August 1, 2009;
29(8):
1213 - 1219.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Mukhopadhyay, M. Rajesh, S. Batkai, Y. Kashiwaya, G. Hasko, L. Liaudet, C. Szabo, and P. Pacher
Role of superoxide, nitric oxide, and peroxynitrite in doxorubicin-induced cell death in vivo and in vitro
Am J Physiol Heart Circ Physiol,
May 1, 2009;
296(5):
H1466 - H1483.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Marfella, C. Di Filippo, M. Portoghese, F. Ferraraccio, M. R. Rizzo, M. Siniscalchi, E. Musacchio, M. D'Amico, F. Rossi, and G. Paolisso
Tight Glycemic Control Reduces Heart Inflammation and Remodeling During Acute Myocardial Infarction in Hyperglycemic Patients
J. Am. Coll. Cardiol.,
April 21, 2009;
53(16):
1425 - 1436.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Di Filippo, R. Marfella, and M. D'Amico
Possible Dual Role of Ubiquitin-Proteasome System in the Atherosclerotic Plaque Progression
J. Am. Coll. Cardiol.,
October 14, 2008;
52(16):
1350 - 1351.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. E. Kanter, M. M. Averill, R. C. LeBoeuf, and K. E. Bornfeldt
Diabetes-Accelerated Atherosclerosis and Inflammation
Circ. Res.,
October 10, 2008;
103(8):
e116 - e117.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Herrmann, S. M. Soares, L. O. Lerman, and A. Lerman
Potential Role of the Ubiquitin-Proteasome System in Atherosclerosis: Aspects of a Protein Quality Disease
J. Am. Coll. Cardiol.,
May 27, 2008;
51(21):
2003 - 2010.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Marfella, C. Di Filippo, M. Portoghese, F. Ferraraccio, B. Crescenzi, M. Siniscalchi, M. Barbieri, C. Bologna, M. R. Rizzo, F. Rossi, et al.
Proteasome Activity as a Target of Hormone Replacement Therapy-Dependent Plaque Stabilization in Postmenopausal Women
Hypertension,
April 1, 2008;
51(4):
1135 - 1141.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y. Takami, H. Nakagami, R. Morishita, T. Katsuya, H. Hayashi, M. Mori, H. Koriyama, Y. Baba, O. Yasuda, H. Rakugi, et al.
Potential Role of CYLD (Cylindromatosis) as a Deubiquitinating Enzyme in Vascular Cells
Am. J. Pathol.,
March 1, 2008;
172(3):
818 - 829.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Marfella, C. D. Filippo, M. T. Laieta, R. Vestini, M. Barbieri, P. Sangiulo, B. Crescenzi, F. Ferraraccio, F. Rossi, M. D'Amico, et al.
Effects of Ubiquitin-Proteasome System Deregulation on the Vascular Senescence and Atherosclerosis Process in Elderly Patients
J. Gerontol. A Biol. Sci. Med. Sci.,
February 1, 2008;
63(2):
200 - 203.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. S. Kelly, A. M. Thelen, D. R. Kaiser, J. M. Gonzalez-Campoy, and A. J. Bank
Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus
Vascular Medicine,
November 1, 2007;
12(4):
311 - 318.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Herrmann, A. M. Saguner, D. Versari, T. E. Peterson, A. Chade, M. Olson, L. O. Lerman, and A. Lerman
Chronic Proteasome Inhibition Contributes to Coronary Atherosclerosis
Circ. Res.,
October 26, 2007;
101(9):
865 - 874.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. Herrmann, L. O. Lerman, and A. Lerman
Ubiquitin and Ubiquitin-Like Proteins in Protein Regulation
Circ. Res.,
May 11, 2007;
100(9):
1276 - 1291.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. Askari, J. E. Kanter, A. M. Sherrid, D. L. Golej, A. T. Bender, J. Liu, W. A. Hsueh, J. A. Beavo, R. A. Coleman, and K. E. Bornfeldt
Rosiglitazone Inhibits Acyl-CoA Synthetase Activity and Fatty Acid Partitioning to Diacylglycerol and Triacylglycerol via a Peroxisome Proliferator-Activated Receptor-{gamma}-Independent Mechanism in Human Arterial Smooth Muscle Cells and Macrophages
Diabetes,
April 1, 2007;
56(4):
1143 - 1152.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. G. Atanasov, I. D. Ignatova, L. G. Nashev, B. Dick, P. Ferrari, F. J. Frey, and A. Odermatt
Impaired Protein Stability of 11beta-Hydroxysteroid Dehydrogenase Type 2: A Novel Mechanism of Apparent Mineralocorticoid Excess
J. Am. Soc. Nephrol.,
April 1, 2007;
18(4):
1262 - 1270.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Quaschning, F. Voss, K. Relle, P. Kalk, N. Vignon-Zellweger, T. Pfab, C. Bauer, F. Theilig, S. Bachmann, A. Kraemer-Guth, et al.
Lack of Endothelial Nitric Oxide Synthase Promotes Endothelin-Induced Hypertension: Lessons from Endothelin-1 Transgenic/Endothelial Nitric Oxide Synthase Knockout Mice
J. Am. Soc. Nephrol.,
March 1, 2007;
18(3):
730 - 740.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. N. DeMaria, O. Ben-Yehuda, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, W. Y.W. Lew, J. A.C. Lima, A. S. Maisel, J. Narula, D. J. Sahn, et al.
Highlights of the Year in JACC 2006
J. Am. Coll. Cardiol.,
January 30, 2007;
49(4):
509 - 527.
[Full Text]
[PDF]
|
 |
|
|